UNDER DEVELOPMENT

Cancer Immuno image_2018-12-28.jpg

MAJOR ADVANCES IN CANCER IMMUNOTHERAPY

Disclosure: Many publications were reviewed and found to be of strong merit. We chose to list only a few of these publications here based on independent review by the Beatty Laboratory and relevance to our work.

2019

FEB 2019 A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 019 Feb 25. doi: 10.1038/s41591-019-0357-y. [Epub ahead of print]

FEB 2019 Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma. Cell. 2019 Feb 25. doi: 10.1038/s41591-019-0357-y. [Epub ahead of print]

JAN 2019 Intratumoral Tcf1+PD-1+CD8+ T cells with Stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity. 2019 Jan 15;50(1):195-211.e10.

JAN 2019 Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1-CD8+ Tumor-Infiltrating T Cells. Immunity. 2019 Jan 15;50(1):181-194.e6.

2018

DEC 2018 Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells. Cell. 2018 Dec 13;175(7):1731-1743.e13.

DEC 2018 NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines. Cell. 2018 Dec 13;175(7):1744-1755.e15.

DEC 2018 Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy. JCI Insight. 2018 Dec 6;3(23). pii: 124507.

DEC 2018 Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12. Immunity. 2018 Dec 18;49(6):1148-1161.e7.

OCT, 2018 Evolution of Metastases in Space and Time under Immune Selection. Cell. 2018 Oct 18;175(3):751-765.e16.

UNDER DEVELOPMENT

2017

2016

2015

2014

2013

2012

2011

2010